Literature DB >> 34782970

Efficacy and side effect profile of two CMV prophylaxis strategies in high and intermediate risk kidney transplant recipients - a multicentre national study.

Trijntje J W Rennie1, Colin G Geddes2, Rhianna McIntyre-McClure3, Bernadine H E Chua4, Wendy Metcalfe5, Ingólfur Johannessen6, Paul J Phelan5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34782970     DOI： 10.1007/s40620-021-01161-4

Source DB:  PubMed          Journal:  J Nephrol        ISSN： 1121-8428            Impact factor:   3.902


× No keyword cloud information.
  3 in total

1.  Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis.

Authors:  Andre C Kalil; Cezarina Mindru; Diana F Florescu
Journal:  Clin Infect Dis       Date:  2010-12-28       Impact factor: 9.079

Review 2.  Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Wang Xin; Yang Hui; Zhang Xiaodong; Cui Xiangli; Wang Shihui; Liu Lihong
Journal:  J Pharm Pharm Sci       Date:  2017       Impact factor: 2.327

3.  Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.

Authors:  Per Ljungman; Michael Boeckh; Hans H Hirsch; Filip Josephson; Jens Lundgren; Garrett Nichols; Andreas Pikis; Raymund R Razonable; Veronica Miller; Paul D Griffiths
Journal:  Clin Infect Dis       Date:  2016-09-28       Impact factor: 9.079
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.